Adam Sims joins SCM's board
This article was originally published in Scrip
Executive Summary
UK-based SCM Pharma, a sterile filling specialist, has appointed Adam Sims to its board of directors. Mr Sims joins the CMO with 20 years' experience in the global pharmaceutical and chemical sector, having most recently served in senior commercial and finance roles at Aesica for seven years.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.